Highlights

  • The unravelling began at the FY25 result on 19 August 2025, when CSL said it would demerge Seqirus as a separately listed…
  • On 10 February 2026, chief executive Paul McKenzie retired with immediate effect.
  • The heaviest blow came on 11 May 2026 with Naylor's 90-day review.
  • CSL's first-half accounts to 31 December 2025 showed Revenue of USD 8.3 billion, down 4 % at constant currency, and underlying NPATA…

CSL Limited hands down its FY26 full-year result on Tuesday 18 August, and few reporting-season events carry more weight. The company that spent a decade as the ASX's Blue-Chip growth story has spent twelve months dismantling and rebuilding itself: a shelved demerger, a chief executive gone without warning, billions in writedowns, and a revenue line set to shrink…

Company Overview

CSL is a Melbourne-headquartered biotechnology group built on three pillars. CSL Behring, by far the largest, collects human plasma across a US centre network and fractionates it into immunoglobulins, albumin and haemophilia therapies. CSL Seqirus is one of the world's largest influenza Vaccine makers. CSL Vifor, acquired in 2022, sells iron deficiency and nephrology products.

Recent Developments

The unravelling began at the FY25 result on 19 August 2025, when CSL said it would demerge Seqirus as a separately listed ASX company by the end of FY26, cut net headcount by up to 15 %, and close 22 underperforming US plasma centres, about 7 % of its collection footprint. Restructuring was costed at USD 700 million to USD 770 million pre-tax for annual savings of USD…

On 28 October 2025 the demerger was deferred indefinitely. CSL cited Volatility in the US influenza vaccine market, flagging an expected 12 % fall in US flu vaccination rates and a 14 % fall among those aged 65 and over, with Seqirus revenue guided to decline by a mid-teens percentage. Chairman Brian McNamee said the timing would be revisited only when market conditions supported maximising Shareholder value.

Financial Snapshot

CSL's first-half accounts to 31 December 2025 showed revenue of USD 8.3 billion, down 4 % at constant currency, and underlying NPATA of USD 1.9 billion, down 7 %. Reported net profit collapsed 81 % to USD 401 million once about USD 1.1 billion of after-tax impairments and most of the restructuring charge were absorbed. NPATA Earnings Per Share of USD 4.03…

Segment detail shows where the damage sits. CSL Behring revenue fell 7 % to USD 5.5 billion, with immunoglobulins down 6 % to USD 3.0 billion and albumin down 27 % to USD 494 million. Seqirus slipped 2 % to USD 1.6 billion. Vifor was the outlier, growing 12 % to USD 1.2 billion.

What to Watch

The FY26 result is scheduled for 10:00am AEST on 18 August, with the AGM on 27 October. Investors will look for FY27 guidance, how much of the flagged USD 5 billion Impairment lands in FY26 versus FY27, progress against the savings target, and word on the permanent CEO appointment. Seqirus operational separation was on track for 1 July 2026, leaving a listing…

Risks

US influenza vaccination rates remain the central uncertainty for Seqirus and, by extension, for any demerger valuation. Immunoglobulin competition could keep Behring's largest Franchise under pressure beyond the destocking explanation, and China albumin pricing has already cost more than expected.

Outlook

CSL enters 18 August with the lowest expectations it has carried in a generation. The questions are narrow: did FY26 land at the reduced USD 15.2 billion revenue and USD 3.1 billion NPATA marks, is the immunoglobulin channel clearing, how much impairment remains, and who will run the company. A credible FY27 number matters more than the FY26…